Dr. Philip Barter of the Heart Research Institute of Sydney, Australia, presented an update of the disappointing ILLUMINATE clinical drug trial for the once-promising drug, torcetrapib, at the 2007 American Heart Association meetings in Orlando, Florida.
The crash and burn of drug manufacturer Pfizer's torcetrapib in December 2006 made headlines and prompted enormous disappointment for many patients and doctors who had hoped for a new drug choice to raise HDL cholesterol. Pfizer...

